Skip to content

Janus Living JAN Accrued litigation

Accrued litigation at other companies

Indivior Pharmaceuticals, Inc.
 logo
Indivior Pharmaceuticals, Inc. INDV

Other financials

Income statement

See full
Revenue$4.7M-2.8%
Gross profit$3.6M+85.6%
Operating income-$2.7M-41.0%
Net income-$271.5M-11,250%
EPS (diluted)-$2.14-1,327%

Balance sheet

See full
Cash & equivalents$10.5M-2.7%
Total debt$107.0K-99.4%
Total equity$889.7M+3,976%
Total assets$959.7M+1,130%

Cash flow

See full
Operating cash flow-$12.3M-764%
CapEx$2.8K
Free cash flow-$1.8M

Valuation

See full
Market cap$5.56B+43,568%
Enterprise value$5.55B+26,232%
P/S231.5×+231×

Profitability

See full
Gross margin46.5%+1.2pp
Operating margin-99.7%-717pp
Net margin-2,552.7%-2,601pp
FCF margin-29.7%

Returns & leverage

See full
Return on equity-134.6%-791pp
Debt / equity-0.5×
Current ratio0.8×0.0×

Where this comes from

Reported directly by Janus Living in its filing.

Tagged under the XBRL concept us-gaap:LitigationReserveCurrent.

The official record: Janus Living ’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janus Living 's accrued litigation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Janus Living 's accrued litigation?
Janus Living (JAN) reported accrued litigation of $660K in Q1 2026.
How has Janus Living 's accrued litigation changed year-over-year?
Janus Living 's accrued litigation increased by 1220.0% year-over-year, from $50K to $660K.
What is the long-term trend for Janus Living 's accrued litigation?
Over 3 years (2022 to 2025), Janus Living 's accrued litigation has grown at a 9.0% compound annual growth rate (CAGR), from $510K to $660K.